Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Blood Cancer UK and RareCan Develop their Partnership

Blood Cancer UK and RareCan Develop their Partnership

4th July 2023

The companies will now concentrate on providing clinical trials that are targeted towards avoiding, recognising or managing uncommon cancers.

With about 16,000 fatalities a year, blood cancer is one of the deadliest forms of cancer in the UK.

The CEO at RareCan, Kotting, expresses his passion towards reaffirmation of the collaboration. “it is fantastic that Blood Cancer UK are actively renewing our partnership to support RareCan’s evolution and for the research community as a whole”

Sarah McDonald at BloodCancer UK evaluated that “each year, around 5,000 people with blood cancer are put on ‘watch and wait’, however, this can often be a worrying time for those living through this experience.”

“where suitable, making people aware of and directing them to RareCan could give more people an opportunity to help researchers, and importantly give them hope that they can make a positive impact for themselves and others on the future”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.